MM-093, a recombinant human alpha-fetoprotein for the potential treatment of rheumatoid arthritis and other autoimmune diseases
Dudich, E.
Current Opinion in Molecular Therapeutics 9(6): 603-610
2007
ISSN/ISBN: 1464-8431 PMID: 18041671 Document Number: 606370
Merrimack Pharmaceuticals Inc (previously Atlantic Biopharmaceuticals) is developing MM-093 (formerly ABI-001), an injectable formulation of a recombinant human alpha-fetoprotein, for the potential treatment of myasthenia gravis, multiple sclerosis, rheumatoid arthritis, autoimmune uveitis and psoriasis. MM-093 is currently undergoing phase II clinical trials for rheumatoid arthritis, psoriasis and autoimmune uveitis.
Document emailed within 1 workday
Related Documents
Azuma, T. 1988: Clinical study of autoimmune diseases: recent trends--with special reference to progress in immunological tests and therapeutic methods. Systemic autoimmune diseases. 4) Rheumatoid arthritis Nihon Rinsho. Japanese Journal of Clinical Medicine 46(4): 883-887Furst, D.E.; Schiff, M.H.; Fleischmann, R.M.; Strand, V.; Birbara, C.A.; Compagnone, D.; Fischkoff, S.A.; Chartash, E.K. 2003: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) Journal of Rheumatology 30(12): 2563-2571
Cuchacovich, M.; Gatica, H.; Pizzo, S.V.; Gonzalez-Gronow, M. 2001: Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases Clinical and Experimental Rheumatology 19(6): 673-680
Miyachi, K.; Takano, S.; Sekiyama, N.; Suzuki, A.; Matsuoka, Y.; Irimajiri, S.; Inagaki, Y.; Kiryu, Y.; Mimori, T.; Akizuki, M. 1994: Two cases of rheumatoid arthritis presenting autoimmune hepatic diseases Ryumachi 34(3): 639-645
Murakami, S. 1976: 2 cases of myasthenia gravis associated with rheumatoid arthritis - a study of autoimmune diseases Rinsho Shinkeigaku 16(2): 110-116
Fleishmann, R.M. 2002: Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents Clinical and Experimental Rheumatology 20(5 Suppl 27: S35-S41
Matsui, H.; Shiraishi, N.; Yasuda, T.; Nezuka, T. 1999: The effects of recombinant human erythropoietin on autologous blood donation in rheumatoid arthritis patients with anaemia Clinical and Experimental Rheumatology 17(1): 69-74
Huang, C-Mei.; Yang, Y-Hsu.; Chiang, B-Luen. 2004: Different familial association patterns of autoimmune diseases between juvenile-onset systemic lupus erythematosus and juvenile rheumatoid arthritis Journal of Microbiology Immunology and Infection 37(2): 88-94
Souness, J.E.; Foster, M. 1998: Potential of phosphodiesterase type of IV inhibitors in the treatment of rheumatoid arthritis Idrugs: the Investigational Drugs Journal 1(5): 541-553
Mitsuyasu, R.T. 1989: The enhanced potential use of recombinant alpha interferon in the treatment of AIDS-related Kaposi's sarcoma Oncology Nursing Forum 16(6): 5-7
Jaller Char, J.J.; Jaller, J.A.; Waibel, J.S.; Bhanusali, D.G.; Bhanusali, N. 2018: The Role of IL-17 in the Human Immune System and its Blockage as a Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Journal of Drugs in Dermatology: Jdd 17(5): 539-542
Carleson, J.; Alstergren, P.; Appelgren, A.; Appelgren, B.; Kopp, S.; Theodorsson, E.; Lundeberg, T. 1996: A model for the study of experimentally induced temporomandibular arthritis in rats: the effect of human recombinant interleukin-1 alpha on neuropeptide-like immunoreactivity Journal of Orofacial Pain 10(1): 9-14
Egnatios, G.; Warthan, M.M.; Pariser, R.; Hood, A.F. 2008: Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors Journal of Drugs in Dermatology: Jdd 7(10): 975-977
Messner, R.P. 1997: The potential of bone marrow stem cell transplantation in the treatment of autoimmune diseases Journal of Rheumatology 24(5): 819-821
Valesini, G.; Montecucco, C.; Cutolo, M. 2006: Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy Clinical and Experimental Rheumatology 24(4): 413-423
Rood, K.; Stiller, R. 2013: Hereditary persistence of alpha-fetoprotein: a rare cause for unexplained alpha-fetoprotein elevations in pregnancy Connecticut Medicine 77(1): 43-45
Seriolo, B.; Paolino, S.; Ferrone, C.; Cutolo, M. 2008: Impact of long-term anti-TNF-alpha treatment on insulin resistance in patients with rheumatoid arthritis Clinical and Experimental Rheumatology 26(1): 159-60; author reply 160
Van Lieshout, A.W.T.; Creemers, M.C.W.; Radstake, T.R.D.J.; Elving, L.D.; van Riel, P.L.C.M. 2008: Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha Journal of Rheumatology 35(5): 938-939
Eto, S.; Fujihira, T. 1988: Clinical study of autoimmune diseases: recent trends--with special reference to progress in immunological tests and the therapeutic methods. Organ-specific autoimmune diseases. 1) Autoimmune thyroid diseases Nihon Rinsho. Japanese Journal of Clinical Medicine 46(4): 894-900
1979: Amniotic-fluid alpha-fetoprotein measurement in antenatal diagnosis of anencephaly and open spina bifida in early pregnancy. Second report of the U.K. Collaborative Study on Alpha-fetoprotein in Relation to Neural-tube Defects Lancet 2(8144): 651-662